Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 115

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 115
---
Service FeesVolume Rebates and ChargebacksGovernment RebatesTotalBalance at December 31, 2024$1,600 $1,308 $4,875 $4,863 $1,707 $14,353 Provision1,051 10,469 17,835 117,974 2,641 149,970 Payments(571)(10,296)(17,756)(117,511)(2,674)(148,808)Balance at September 30, 2025$2,080 $1,481 $4,954 $5,326 $1,674 $15,515 

September 30, 2024Returns AllowancesPrompt Payment DiscountsService FeesVolume Rebates and ChargebacksGovernmentRebatesTotalBalance at December 31, 2023$1,868 $1,308 $3,697 $5,870 $1,175 $13,918 Provision1,409 9,260 15,109 81,037 1,955 108,770 Payments(1,975)(9,360)(14,973)(82,770)(1,090)(110,168)Balance at September 30, 2024$1,302 $1,208 $3,833 $4,137 $2,040 $12,520 

Total reductions of gross product sales from sales-related allowances and accruals were $150.0 million and $108.8 million, or 22.1% and 17.6% of gross product sales, for the nine months ended September 30, 2025 and 2024, respectively. The overall 4.5% increase in sales-related allowances and accruals as a percentage of gross product sales was primarily related to accruals as a result of higher chargeback-related allowances from expanded contracting efforts.

Cost of Goods Sold 

Cost of goods sold primarily relates to the costs to produce, package and deliver our products to customers. These expenses include labor, raw materials, manufacturing overhead and occupancy costs, depreciation of facilities, quality control and engineering. 

The following table provides information regarding our cost of goods sold and gross margin during the periods indicated, including percent changes (dollar amounts in thousands):

Three Months EndedSeptember 30,% Increase / (Decrease)Nine Months EndedSeptember 30,% Increase / (Decrease)202520242